ZURICH, Switzerland – February 27, 2026
Veraxa Biotech AG announced that its shareholders have approved the previously disclosed business combination with Voyager Acquisition Corp., marking a significant milestone toward becoming a publicly traded oncology-focused biotechnology company. The transaction, structured as a SPAC merger, is designed to accelerate Veraxa’s clinical and preclinical oncology programs, expand research and development capabilities, and strengthen its capital position to support long-term growth in next-generation cancer therapeutics.
The proposed merger reflects continued investor interest in innovative oncology platforms, particularly companies advancing antibody-drug conjugates (ADCs) and bispecific T-cell engagers (TCEs). Veraxa Biotech focuses on developing precision immuno-oncology therapies targeting difficult-to-treat solid tumors and hematologic malignancies. The company’s pipeline includes proprietary engineered antibody platforms intended to improve tumor selectivity, enhance immune activation, and reduce off-target toxicities.
Capital Markets Strategy to Accelerate Oncology Pipeline
The business combination with Voyager Acquisition Corp., a special purpose acquisition company (SPAC) targeting healthcare innovation, is expected to provide Veraxa with enhanced access to public capital markets. Upon completion of the merger, the combined entity is anticipated to be listed on Nasdaq, enabling broader investor participation and increased visibility within the global biotech sector.
According to the announcement, shareholder approval represents a critical step toward finalizing the transaction, subject to customary closing conditions and regulatory requirements. The additional capital raised through the SPAC structure is expected to support clinical trial advancement, manufacturing scale-up, and expansion of translational research programs. With oncology remaining one of the most capital-intensive therapeutic areas, access to sustained funding is essential for advancing investigational biologics through early- and late-stage development.
Advertisement
Strengthening Position in Antibody-Based Cancer Therapies
Veraxa’s research strategy centers on leveraging advanced antibody engineering to enhance therapeutic precision. The company’s platform is designed to generate next-generation bispecific antibodies and antibody-drug conjugates capable of selectively targeting tumor-associated antigens while activating immune effector cells. These approaches aim to address limitations seen in earlier immunotherapies, including resistance mechanisms and limited durability of response.
The oncology drug development landscape has increasingly favored innovative biologics that combine tumor targeting with immune modulation. By positioning itself within this segment, Veraxa seeks to capitalize on growing demand for differentiated immuno-oncology therapies. The SPAC merger is intended to accelerate development timelines and broaden the company’s operational footprint.
Outlook and Industry Context
SPAC transactions in the biotech industry have evolved over recent years, with investors placing greater emphasis on clinical-stage assets and clearly defined regulatory pathways. Veraxa’s shareholder-backed approval signals confidence in its pipeline potential and corporate strategy. As regulatory scrutiny and market expectations continue to shape biotech financing, access to public markets can provide both funding stability and enhanced governance oversight.
If completed, the merger would establish Veraxa as a publicly traded oncology innovator focused on advancing antibody-based therapies across multiple tumor types. The transaction underscores ongoing consolidation and capital formation trends within the global life sciences ecosystem, particularly among companies developing high-risk, high-reward cancer therapeutics.
By aligning strategic financing with scientific innovation, Veraxa aims to strengthen its ability to deliver transformative oncology treatments while navigating the increasingly competitive immuno-oncology landscape.
Source: VERAXA press release
